Search research articles
Contact Us
Filters
Showing results (881-890 of 908) with videos related to
Page
of 91
Sort By:
Vaccine
|
April 3, 2026
Immunogenicity and safety of a quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha): A randomized controlled phase 2 non-inferiority clinical trial
Sensen Yang, Defang Dai, Zhuang Kang, et al.
Science (New York, N.Y.)
|
June 13, 2024
Metabolic inflexibility promotes mitochondrial health during liver regeneration
Xun Wang, Cameron J Menezes, Yuemeng Jia, et al.
The Journal of Clinical Investigation
|
October 20, 2020
Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer
Fang Huang, Kenneth E Huffman, Zixi Wang, et al.
Science (New York, N.Y.)
|
November 6, 2025
NUDT5 regulates purine metabolism and thiopurine sensitivity by interacting with PPAT
Zheng Wu, Phong T Nguyen, Varun Sondhi, et al.
Cancer Medicine
|
December 21, 2016
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
The Lancet. Infectious Diseases
|
July 20, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial
Feng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, et al.
Science Advances
|
November 17, 2021
Felsic volcanism as a factor driving the end-Permian mass extinction
Hua Zhang, Feifei Zhang, Jiu-Bin Chen, et al.
Cancer Medicine
|
July 16, 2019
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
National Science Review
|
October 22, 2021
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
Li Zhang, Lei Cao, Xing-Su Gao, et al.
Cancer Discovery
|
October 12, 2022
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
Junhua Lyu, Yuxuan Liu, Lihu Gong, et al.
Page
of 91
Search research articles
Search
Showing results (881-890 of 908) with videos related to
Sort By:
Page
of 91
Vaccine
|
April 3, 2026
Immunogenicity and safety of a quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha): A randomized controlled phase 2 non-inferiority clinical trial
Sensen Yang, Defang Dai, Zhuang Kang, et al.
Science (New York, N.Y.)
|
June 13, 2024
Metabolic inflexibility promotes mitochondrial health during liver regeneration
Xun Wang, Cameron J Menezes, Yuemeng Jia, et al.
The Journal of Clinical Investigation
|
October 20, 2020
Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer
Fang Huang, Kenneth E Huffman, Zixi Wang, et al.
Science (New York, N.Y.)
|
November 6, 2025
NUDT5 regulates purine metabolism and thiopurine sensitivity by interacting with PPAT
Zheng Wu, Phong T Nguyen, Varun Sondhi, et al.
Cancer Medicine
|
December 21, 2016
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
The Lancet. Infectious Diseases
|
July 20, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial
Feng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, et al.
Science Advances
|
November 17, 2021
Felsic volcanism as a factor driving the end-Permian mass extinction
Hua Zhang, Feifei Zhang, Jiu-Bin Chen, et al.
Cancer Medicine
|
July 16, 2019
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
National Science Review
|
October 22, 2021
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
Li Zhang, Lei Cao, Xing-Su Gao, et al.
Cancer Discovery
|
October 12, 2022
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
Junhua Lyu, Yuxuan Liu, Lihu Gong, et al.
Page
of 91